The RESTORE Study

Mitchell, Paul; Bandello, Francesco; Schmidt‐Erfurth, Ursula; Lang, Gabriele E.; Massin, Pascale; Schlingemann, Reinier O.; Sutter, Florian; Simader, Christian; Burian, Gabriela; Gerstner, Ortrud; Weichselberger, Andreas

doi:10.1016/j.ophtha.2011.01.031

articleOphthalmologyApr 1, 2011HYBRID OA

The RESTORE Study

PMPaul Mitchell FBFrancesco Bandello USUrsula Schmidt‐Erfurth GEGabriele E. Lang PMPascale Massin

Westmead Institute · Millennium Institute · +12 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Objective

To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME).

Design

A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study.

Citation impact

1,328

total citations

FWCI: 87.36
Percentile: 100%
References: 21

Citations per year

Authors

PM
Paul MitchellCorresponding
Westmead Institute, Millennium Institute, University of Sydney
FB
Francesco Bandello
Vita-Salute San Raffaele University
US
Ursula Schmidt‐Erfurth
University of Vienna
GE
Gabriele E. Lang
University Hospital Ulm
PM
Pascale Massin
Hôpital Lariboisière

Topics & keywords

Topics

Retinal Diseases and Treatments97%
Ocular Diseases and Behçet’s Syndrome1%
Ophthalmology and Visual Impairment Studies0%

Keywords

Medicine
Ranibizumab
Ophthalmology
Pro re nata
Visual acuity
Laser treatment
Diabetic retinopathy
Diabetic macular edema

No related works found for this paper.